Pfizer raised its 2026 full-year revenue guidance following Q2 earnings that beat Wall Street expectations, driven by strong sales of Eliquis, an anticoagulant drug. The company reported Q2 adjusted EPS of $0.77, above analyst estimates of $0.68, and is also pursuing new drug launches and a $10 billion acquisition of Metsera to enter the obesity treatment market, signaling a strategic pivot away from COVID-related products as patent expirations loom.